ADC Development Services Targeting CD147

Cluster of differentiation 147 (CD147) is a potential target of treatment against human non-small cell lung cancer (NSCLC). As an emerging cancer therapy, antibody-drug conjugates (ADCs) can achieve targeted deliver of potent agents to tumor sites, thereby reducing systemic toxicity while enhancing target cell killing activity. With Ph.D. level scientists and over a decade of experience in antibody discovery, antibody engineering, synthetic chemistry, and bio-conjugation, Creative Biolabs is dedicated to meeting our clients' unique needs of developing their own anti-CD147 ADC. Moreover, commercial Anti-CD147 ADCs product for research are also available at Creative Biolabs.

Introduction of CD147

CD147, a transmembrane protein of the immunoglobulin (Ig) superfamily, is highly expressed on various epithelial malignancies, including pancreas carcinoma, breast cancer, prostate carcinoma, bladder carcinoma, hepatocellular carcinoma, and lung cancer. As shown in Fig.1, CD147 contains a 185-aa extracellular domain composed of two Ig loops (EC I and EC II), a short transmembrane domain (TD), and a 39-aa cytoplasmic domain (CD). CD147 originally promotes membrane-type matrix metalloproteinase secretion, and induces tumor cell invasion, migration and even angiogenesis, all of which contribute to tumorigenesis. In addition, it is reported that expression levels of CD147 are closely associated with poor prognosis. Therefore, CD147 represents a promising therapeutic target for cancer.

Fig.1 The diagram illustrates the structure of CD147. (Zhu, 2014)

Anti-CD147 ADC in NSCLC ADC Service

Recently, targeted therapy has become a novel option for the treatment against NSCLC with some exciting advances. For instance, HcHAb18-DM1, a novel anti-CD147 ADC, combines a humanized chimeric human-mouse monoclonal IgG1 antibody (HcHAb18) as the targeting component with a potent cytotoxic drug maytansinoid derivative (DM1) as the payload component, via a non-cleavable thioether linker (SMCC) as the linking component. Upon binding to CD147, HcHAb18 could be efficiently internalized. HcHAb18-DM1 displayed an impressive potency in vitro and in vivo with a favorable safety profile and becomes a promising CD147-targeted therapeutic for NSCLC.

Fig.2 The structure of HcHAb18-DM1. (Huhe, 2019)

What Can We Do for You?

Antigen-antibody binding and targeting cells with high growth rate are two integral prerequisites for exerting anti-tumor activity of CD147-targeted ADC. Many suitable antibodies and antibody conjugates for specific target recognition can be obtained through our well-established ADC Antibody Screening platform . Creative Biolabs also offer Antibody Humanization Services to elegantly engraft the selected antibody CDR regions into the most suitable human framework for ADCs designated in human uses. Besides, a successful antibody used in ADC should also exert strong tendency for internalization after antigen binding. For ADC assembly, commercial SMCC-DM1 Product and other Drug-linker Complexes by using DrugLnk™ Custom Synthesis platform are available for you. According to client's specific demands, customized linker-drug complexes preparation services, ADC in vivo Analysis and ADC in vitro Analysis could be supplied too. If you are looking for ADC development services targeting CD147, Creative Biolabs will be your best choice. Please don't hesitate to contact us for more information.

References

1. Zhu, X.; et al. CD147: a novel modulator of inflammatory and immune disorders. Current medicinal chemistry. 2014, 21(19): 2138-2145.
2. Huhe, M.; et al. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochemical and biophysical research communications. 2019, 513(4): 1083-1091.

For Research Use Only. NOT FOR CLINICAL USE.